

SEND for CBER What You Need to Know

Lisa Lin

Office of Director, Center for Biologics Evaluation & Research, U.S. Food & Drug Administration

Nabil Al-Humadi

Office of Vaccine Research & Review, Center for Biologics Evaluation & Research, U.S. Food & Drug Administration

Susan DeHaven

Translational Medicine & Early Development, Sanofi US Inc.

SBIA Webcast – December 4, 2020

Learning Objectives



- Describe CBER's requirement and support on SEND for CBER
- Understand the important data points for CBER non-clinical studies
- Understand the perspective from review's point of view
- Understand the future development on SEND for CBER



SEND for CBER Requirement Date



"The Center for Biologics Evaluation and Research (CBER) intends to receive SEND datasets in future submissions."

Use Data Exchang Standard		e Data Exchange Supported Standard Guide Version			Date Support Ends (MM/DD/YYYY)	Date Requirement Begins (MM/DD/YYYY)
Animal study datasets	SEND	3.1	CDER	08/21/2017		03/15/2019 [1] 03/15/2020 [2]
Animal study datasets	SEND	3.1	CBER	03/15/2021		03/15/2023



We are on the way! Assessing, Analyzing, Recommending, Piloting, Implementing

www.fda.gov

Federal Register Notice was published in July 2020, announcing CBER's support and future requirement for SEND

PUBLISHED DOCUMENT

AGENCY:

Food and Drug Administration, HHS.

ACTION:

Notice.

SUMMARY:

The Food and Drug Administration (FDA or Agency) Center for Biologics Evaluation and Research (CBER) is announcing support for the current version of Clinical Data Interchange Standards Consortium (CDISC) Standard for the Exchange of Nonclinical Data (SEND) and an update to the FDA Data Standards Catalog for the submission of nonclinical data in new drug applications (NDAs), abbreviated new drug applications (ANDAs), certain biologics license applications (BLAs), and certain investigational new drug applications (INDs). This update does not apply to noncommercial INDs for a product that is not intended for commercial distribution (research and investigator-sponsored INDs); INDs and BLAs for devices that are regulated by CBER as biological products under the Public Health Services (PHS) Act; and submissions for blood and blood components, including Source Plasma.

Start Printed Page 42412

DOCUMENT DETAILS

Printed version: PDF

Publication Date: 07/14/2020

Agencies: Food and Drug Administration

Document Type: Notice

Bocument Citation: 85 FR 42411

Page: 42411-42412 (2 pages)

Agency/Docket Number: Docket No. FDA-2020-N-1313

Document Number: 2020-15095

DOCUMENT DETAILS

OCUMENT STATISTICS

Page views: 927 as of 11/03/2020 at 12:15 pm EST FD/



CBER Review Offices

Review (OBRR)

•

www.fda.gov


 Office of Tissues and Advanced Therapies (OTAT)

Office of Blood Research and

Office of Vaccine Research

and Review (OVRR)









Office of Vaccine Research and Review (OVRR)

Products Reviewed

- Vaccines for prevention or treatment of infectious disease indications only
- Allergenics
- Miscellaneous biologics:
 - Fecal microbiota transplants
 - Probiotics
 - Phage products
- Nonclinical Studies
 - Single and repeat dose toxicology
 - Developmental and reproductive toxicology (DART)
 - Genotoxicity, safety pharmacology (allergenics)
 - Immunogenicity
 - Proof-of-concept, efficacy
 - Biodistribution
 - No chronic toxicity or carcinogenicity
- Data Consideration
 - Timing of endpoints following vaccinations
 - Draize Scoring
 - Body temperature
 - Acute phase reactants
 - Immunogenicity/Serology Assays
 - Injection site histology

Study and data types well aligned with SEND roadmap



Office of Tissues and Advanced Therapies (OTAT)

Products Reviewed


- Stem cell and stem-cell-derived products
- Somatic cell products
- Xenotransplantation products
- Certain devices and combination products
- Therapeutic vaccines
- Recombinant or plasma derived proteins
- Wound healing products
- Gene therapy

* Nonclinical Studies

- Proof-of-concept/safety/toxicity
- Cell-fate/biodistribution, typically no PK studies
- Differentiation/integration capacity
- Tumorigenicity: required for stem cell therapy
- Biocompatibility (implantable scaffolds)
- Immunogenicity (therapeutic vaccines)

Data Consideration

- Animal model of disease/injury
- Hybrid safety and activity studies
- Distribution/biodistribution assessments
- Biocompatibility of devices



SEND for CBER Team has been working closely with CDISC on developing IS Domain for Nonclinical Immunogenicity Data


Office of Blood Research and Review (OBRR)

Products Reviewed

- Modified blood components
- Hemoglobin-based oxygen carriers
- Container-closure systems
- Process-related impurities
- Excipients
- Pathogen reduction systems

Nonclinical Studies

- Focused on biocompatibility
- Extractables and leachables testing
- Container closure systems
- Occasionally see developmental or embryo-fetal toxicology for replacement proteins
- Proof-of-concept
- Carcinogenicity
- Data Consideration
 - GLP-compliant toxicology studies only requested on a case-by-case
 - Most nonclinical studies received are not amenable to SEND data
 - Systemic toxicity (biocompatability, hemoglobin-based oxygen carriers),
 - Mutagenicity (impurities, extractables, leachables)



Most Nonclinical studies are not amenable to SEND data

www.fda.gov



- Provide Training & Support for Reviewers
 - CDISC study data standards
 - Analysis tools including JMP, JMP Clinical, SEND Explorer
 - Going through data standards validation check
 - Exploring data by using tools and evaluating define.xml and non-clinical study data reviewers guide



SEND Importance in the View of a Reviewer Precision vs Time

Nabil Al-Humadi, Ph.D. CBER/FDA



Disclaimer:

This presentation reflects the views of the author and should not be construed to represent FDA's views or policies."



What is most important for reviewers to complete their job?

To review a large amount of data requires Time. This time is required for accuracy in summarizing the findings to reach the right conclusion.



Time Importance

 Time is very critical when it comes to an emergency situation. The best example is the corona virus pandemic. In this kind of situation, submission of the data in an organized, easy to evaluate way is very important. One of the most important features of SEND is that the reviewer will receive the data in very organized, easy to review modules.



What are the types and amount of data we receive to review??

Study designs for Tox studies

- Includes 2, 3, 4 or sometimes up to 8 groups
- Males and Females
- Main study sacrifice and Recovery sacrifice
- Termination might varies on the study design as some studies might include multiple termination time points (Days 3, 7, 15, 30, 45... etc.)

Table of general in-life assessments

Parameter	Frequency	Comments
Mortality/ Moribundity Checks ^a	Twice daily (morning and afternoon) beginning upon arrival through termination.	Animals were observed within their cage unless removal was necessary for identification or confirmation of possible findings.
Postdose Observations*	On each dosing days; predose and at 2 hours (±15 minutes) postdose after the end of each group for each sex (for exceptions, see appendix 1).	Cage side observation unless removal was necessary for identification or confirmation of possible findings.
Cageside Observations ^a	Once daily, on non-dosing days, during the dosing phase and recovery period.	Cage side observation unless removal was necessary for identification or confirmation of possible findings.
Detailed Clinical Observations ⁸	At least every 2 weeks during the prestudy period then weekly starting day -1.	Animals were removed from the cage or handled in the cage.
Dermal Scoring ^a	Daily, starting day 1, predose on dosing days (for exceptions, see appendix 1).	Each animal had the dose injection sites examined according to the modified Draize scoring scale.
Individual Body Weights ^a	Once during week-2, two to three times during week -1, daily during week dosing, and twice weekly during the recovery period.	Fasted weight on the day of necropsy.
Food Consumption	Once daily; from at least week -1 and throughout the study	Quantitatively measured; daily measurement was reported.
Body Temperature ^a	Daily from day -5 to day -1, on dosing days: pre-dose and at 3, 6, and 24 hr postdose.	Collected using a subcutaneous implant. When the body temperature of any animal was over 39.5°C, it was recorded daily (only the animal concerned was recorded) until it returned to normal (for exceptions, see appendix 1). Body temperature was measured at approximately the same hour on every measurement day, between 7 and 9 AM during prestudy period and on non-dosing days (where applicable) (for exceptions, see appendix 1).
Ophthalmic Examinations	All animals: once prestudy. Group 1 to 4 on day 3 and the day prior to necropsy (scheduled animals only).	All animals were subjected to funduscopic (indirect ophthalmoscopy) and biomicroscopic (slit lamp) examinations. The mydriatic used was 1% tropicamide



* Minimum required frequency for this parameter indicated.



Table of samples for clinical pathology evaluation

Group Nos.	Population	Occasion/ Time Point	Hematology	Coagulation	Clinical Chemistry	Biomarker (CRP)
All animals	-	Prestudy	Х	Х	Х	Х
l to 4	Interim Recovery Study	Day 3	х	х	х	х

Group Nos.	Group Nos. Population Occasion/ Time Point		Hematology	Coagulation	Clinical Chemistry	Biomarker (CRP)
1 to 4	l to 4 Study At terminatio Day 3		х	х	х	х
1 to 4	Interim		-	-	-	х
1 to 4	Interim Recovery Study	At termination Day 15	х	х	х	х
Overnight F	asting:		-	-	Yes	-
Method/Con	iments:		Appropriate auricular vessel	Appropriate auricular vessel	Appropriate auricular vessel	Appropriate auricular vessel
Target Volui	ne ^a (mL):		0.7	1.2	0.7	0.5
Anticoagular	nt:		EDTA	Sodium citrate	None, in SST	None, in SST
Processing:	sing:		None	Plasma	Serum	Serum

Hematology Parameters

RED BLOOD CELLS	Hematocrit (Hct) Hemoglobin Conc. (Hb) Mean Corp. Hb. (MCH) Mean Corp. Hb. Conc. (MCHC), Mean Corp. Volume (MCV) Total Erythrocyte Count (RBC) Reticulocytes
WHITE BLOOD CELLS	Macrophage Lymphocyte count Large Unstained Cells (LUC) Basophils Neutrophil Monocyte Eosinophil
CLOTTING POTENTIAL	Prothrombin time Activated partial-thromboplastin time clotting time Platelet count Fibrinogen
OTHERS	Bone marrow cytology

Serum Chemistry Parameters



ELECTROLYTE BALANCE	Calcium, chloride, potassium, sodium, phosphorus
CARBOHYDRATE METABOLISM	Glucose
LIVER FUNCTION:	Alanine aminotransferase (ALT or SGPT)
A) HEPATOCELLULAR	Aspartate aminotransferase (AST or SGOT)
B) HEPATOBILIARY	Total bilirubin Alkaline phosphatase (ALP) GGT
ACUTE PHASE REACTANTS	Fibrinogen C-reactive protein (CRP)
KIDNEY FUNCTION	Blood Urea Nitrogen (BUN) Creatinine
OTHERS	Albumin (A)
(ACID/BASE BALANCE,	Total protein Carbon dioxide
CHOLINESTERASES, HORMONES, LIPIDS,	Globulin
METHEMOGLOBIN, AND PROTEINS)	A/G ratio
	Total Cholesterol
	Lactate dehydrogenase
	Fasting Triglycerides
	SDH Creatine kinase

Table of sample collection for immunogenicity

aore of sample e	onection for minute	nogemeny			
Group Nos.	Population	Population Occasion/Time Point		Investigation	
All animals	-	Prestudy	X	X	
1 to 4	Interim Recovery Study	Day 15	х	х	
Method/Comments			Appropriate auricular vessel	Appropriate auricular vessel	
Target Volume (m	L):		0.5	2	
Anticoagulant:		None, in SST	None, in SST		
Processing:		Serum	Serum		



X = Sample collected; SST = Serum separator tube; ADA = Anti-drug antibody

Table of interim main and recovery study terminal procedures

	Scheduled Eu	thanasia Day	Necr	opsy Proced	ures	The	Manager				
Group No.	Main	Recovery	Necropsy	Tissue Collection	Organ Weights	Histology Processing	Microscopic Evaluation				
1 2 3 4	Day 3	Day 15	х	Full List ^a	Full List ^a	Full List ^a	Full List ^a				

X = Procedure conducted.

See tables below.

Table of organs weighed at necropsy

Brain	Heart
Epididymis*	Kidney*
Galibladder ^d	Liver
Gland, adrenal ^a	Lung
Gland, seminal vesicle ^b	Ovary
Gland, parathyroid ^e	Spleen
Gland, pitustary	Testis
Gland, prostate	Thymus
Gland, thyroid ^a	Uterus/Cervix

Paired organ weight.

^b Weighed with prostate

Weighed with thyroid

4 Weighed with liver

Table of tissue collection and preservation

Animal identification Artery, aorta Body cavity, nasal Bone manow smear^a Bone marrow, stemum Bone, femur, right Bone, sternum Brain Bronchi (mainstem) Diaphragm Epididymis Esophagus Ever Gallbladder Ganghon, dorsal root, lumbar Gland, adrenal Gland, lacrimal Gland, harderian Gland, mammary Gland, parathyroid Gland, pituitary Gland, prostate Gland, salivary, submandibular Gland, salivary, sublingual Gland, salivary, parotid Gland, seminal vesicle Gland thyroid Gross lesions/masses Gut-associated lymphoid tissued Heart Joint, femorotibial, right Kidney Large intestine, appendix Large inestine, cecum Large intestine, colon

Large intestine, rectum Larynx Liver Lung Lymph nodes draining administration sites: inguinal, iliac, and sacral Lymph node, mandibular Lymph node, mesenteric Muscle, skeletal (biceps femoris) Nasopharynx Nerve, optic Nerve, sciatic Nerve, tibial Oropharynx Ovary Oviduct Pancreas Site, administration: dorso-lumbar region* Skin Skin overlying the injection site Small intestine duodenum Small intestine, ileum Small intestine, jejunum Small intestine, sacculus rotundus Spinal cord (cervical, thoracic, and lumbar) Spleen Stomach Testis Thymus Tongue Trachea Ureter Urinary bladder Uterus/Cervix Vagina

FDA U.S. FOOD & DRUG

* Three bone marrow smears collected from the 5th to 7th rib were prepared from each euthanized animal, air dried, fixed in methanol, and stained with Wright's Giemsa stain.

^b Preserved in Modified Davidson's fixative.

^c Preserved in Davidson's fixative.

^d From small intestine: Peyer's patch or solitary lymphoid follicle.

^a 3 sections collected per injection site.

DART endpoints

- Use ICH S5(R2) for each period's reproductive and developmental endpoints
- Mating period
 - Mating and Fertility Indices
- Gestational period
 - Maternal evaluation
 - corpora lutea
 - implantation sites
 - pre- & post-implantation losses
 - Fetal and placental weights



DART endpoints



Gestational period

- Fetal external evaluation
- Fetal visceral evaluation
- Fetal skeletal evaluation plus ossification sites
- Lactational period
 - Litter evaluations
 - Lactation and Survival Indices
 - Pup Developmental Landmarks

Immunological endpoints

- Serum antibody determination
 - F0 female predose, end of gestation and lactation
 - F1 fetus cord blood
 - F1 pup (PND 21)
- Additional assessments (case-by-case)
 - If vaccine-induced adverse effects, e.g. histochemical analysis for antibody depositions
 - Neurological assessments
 - Immunological endpoints in Developmental Immunotoxicity Study






How could SEND help us? Organize the data, help us review the data in an efficient way, and provide a tool to create tables and graphs to present the most important findings.

Temperature Levels






Cut off Temperature of 40 °C is very easy to locate in any group from this graph.

www.fda.gov


Body Weight Changes



Body weight changes in test article-treated groups are easy to find when compared to the control groups

www.fda.gov


Creatine Kinase Levels



Creatine Kinase increases are markers of inflammation due to test article treatment


www.fda.gov

C-Reactive Protein Levels



Cut off level of 40 mg/L of the acute phase reactant [CRP] increases (another marker of inflammation) in any group is easy to read from this graph **www.fda.gov**

Neutrophils count



Clinical chemistry findings of neutrophil's levels is obvious in this graph

www.fda.gov

Microscopic Findings-Table

| LINDCHADYADI C | | | | 44 | | | 1

 | 1.1
 |
 | 1
 | 4/02 |
 | | | | _ | -
 | |
|---|--|--|---|---|--|---
--

--

--
--	---
--	--
--	
	NON NEODI ASTIC

 |
 |
 |
 | 10 | -
 | | +++ | | - |
 | |
| | | | | 1 | | - |

 |
 | -
 |
 | 0 | +
 | | - | 100 | |
 | |
| In the Calculation of the Calculation | | | | 4 | - | - | -
 |

 | -
 | | 0
 | - | - | 1
 | 111 | - | | - |
| | | | | 1 | | |

 |
 | -
 |
 | | 1
 | 1.1 | - | | 100 | -
 | |
| Increased celularity | NUN-NEUPLASTIC | | ST HILDE | 2 | - | 1 |

 |
 | 1.1
 |
 | 0 | -
 | | | | | -
 | 1 |
| | | LYMPHING | DE ILIAC Examined: | 20 | 1.1 | 1 | 1 1

 | 11
 | -1.
 | 1 1
 | 10 | 1
 | 1 1 | 1 | 1 1 | 1 1 | -1
 | 1 |
| UNREMARKABLE | | | i harrow water | 18 | 100 | |

 |
 |
 | 1 1
 | 10 | 12.57
 | 1.1 | | | |
 | |
| | | | | 2 | - | | _

 |
 |
 |
 | 0 |
 | | 1 | | 1 | _
 | 1.1 |
| | LYMP | H NODE MES | ENTERIC Examined: | 18 | 101 | 1 | 1.3

 | 1.1
 | 1.
 | 1 1
 | 10 | 1
 | 1 1 | | 1 1 | | 1 1
 | 8 |
| UNREMARKABLE | | | | 20 | | | 3 2

 | 10
 |
 | 3.3
 | 10 | 12
 | 1.1.1 | | | 3.5 |
 | 10 |
| Cellular debris | NON-NEOPLASTIC | 1 OF 5 | | | | |

 |
 |
 |
 | 0 | 1.1
 | | | | |
 | |
| HEMORRHAGE | NON-NEOPLASTIC | 1 OF 5 | | 1 | | |

 |
 |
 |
 | 0 |
 | | | | |
 | |
| HEMORRHAGE | NON-NEOPLASTIC | 2 OF 5 | | 2 | | |

 |
 |
 |
 | 0 | 1
 | | 2 | | |
 | 3 |
| Infiltration, mixed cell | NON-NEOPLASTIC | 1 OF 5 | | 3 | | |

 |
 |
 |
 | 0 |
 | 1 1 | | | |
 | 1 |
| Infiltration, mononuclear cell | NON-NEOPLASTIC | 1 OF 5 | | 5 | | |

 |
 |
 |
 | 0 |
 | 1 1 | 1 | 2 | | 1
 | 1 |
| Inflammation, mixed cell | NON-NEOPLASTIC | 2 OF 5 | | 2 | | |

 |
 |
 |
 | 0 |
 | 1 | 1 | | |
 | 1 |
| Inflammation, mixed cell | NON-NEOPLASTIC | 3 OF 5 | | 2 | | |

 |
 |
 |
 | 0 |
 | | 15 | | |
 | 12 |
| Inflammation, mononuclear cell | NON-NEOPLASTIC | 1 OF 5 | | 1 | | | 1

 |
 |
 |
 | 1 |
 | | | | |
 | 10 |
| Necrosis | NON-NEOPLASTIC | 2.0F.5 | | 1 | | |

 |
 |
 |
 | 0 |
 | 1 | | | |
 | |
| Necrosis | NON-NEOPLASTIC | 3 OF 5 | | 2 | | |

 |
 |
 |
 | 0 | 1
 | 111 | 11 | | |
 | 12 |
| | | SITE APP | ICATION Examined | 20 | 1 1 | .1. | 1 1

 | 1 1
 | . 1
 | 1 1
 | 10 | 1
 | 1 1 | 1 | 1 1 | 1 1 | 1.1
 | 10 |
| UNREMARKABLE | | | | 11 | 1 | 111 | 1 1

 | 1 1
 | 111
 | 1 1
 | 10 |
 | 110 | | | 1 |
 | 1 |
| Increased cellularity | NON-NEOPLASTIC | 1 OF 5 | | 14 | | |


 |
 |
 |
 | 0 |
 | - | 112 | 1 1 | | 1
 | 1 |
| | | | | 5 | | |

 |
 |
 |
 | 0 | 1
 | 1 1 | 1.1 | | |
 | |
| | | 2020-20 | SPLEEN Examined | 20 | 1.1 | 1 | 1 1

 | 1.1
 | 1
 | 1 1
 | 10 | 1.1
 | 1 1 | 1 | 1 1 | 1 1 | 1 1
 | 10 |
| | HEMORRHAGE
HEMORRHAGE
Infiltration, mixed cell
Infiltration, mononuclear cell
Inflammation, mixed cell
Inflammation, mixed cell
Inflammation, mononuclear cell
Necrosis
Necrosis | Erythrocytosis NON-NEOPLASTIC
Increased cellularity NON-NEOPLASTIC
Increased cellularity NON-NEOPLASTIC
Increased cellularity NON-NEOPLASTIC
UNREMARKABLE
Cellular debris NON-NEOPLASTIC
HEMORRHAGE NON-NEOPLASTIC
HEMORRHAGE NON-NEOPLASTIC
Infiltration, mixed cell NON-NEOPLASTIC | Erythrocytosis NON-NEOPLASTIC 1 OF 5 Increased cellularity NON-NEOPLASTIC 1 OF 5 Increased cellularity NON-NEOPLASTIC 2 OF 5 Increased cellularity NON-NEOPLASTIC 3 OF 5 UNREMARKABLE LYMPH NODE LYMPH NODE UNREMARKABLE NON-NEOPLASTIC 1 OF 5 Infiltration, mixed cell NON-NEOPLASTIC 1 OF 5 Infiltration, mixed cell NON-NEOPLASTIC 2 OF 5 Infiltration, mixed cell NON-NEOPLASTIC 3 OF 5 Infiltration, mixed cell NON-NEOPLASTIC 3 OF 5 Infiltration, mixed cell NON-NEOPLASTIC 3 OF 5 Infiltration, mixed cell NON-NEOPLASTIC 1 OF 5 Infiltration, mixed cell NON-NEOPLASTIC 3 OF 5 Infiltration, mixed cell NON-NEOPLASTIC 1 OF 5 Infiltration, mononuclear cell NON-NEOPLASTIC 2 OF 5 Infiltration, mon | Erythrocylosia NON-NEOPLASTIC 1 OF 5 Increased cellulanty NON-NEOPLASTIC 1 OF 5 Increased cellulanty NON-NEOPLASTIC 2 OF 5 Increased cellulanty NON-NEOPLASTIC 3 OF 5 UNREMARKABLE UNREMARKABLE UNREMARKABLE UNREMARKABLE UNREMARKABLE OUNREMARKABLE UNREMARKABLE OUNREMARKABLE OUNREMARKABLE OPLASTIC ON-NEOPLASTIC OF 5 HEMORRHAGE NON-NEOPLASTIC OF 5 Infiltration, mixed cell NON-NEOPLASTIC Infiltration, mixed cell | Erythrocytosis NON-NEOPLASTIC 1 OF 5 1 Increased cellularity NON-NEOPLASTIC 1 OF 5 2 Increased cellularity NON-NEOPLASTIC 2 OF 5 7 Increased cellularity NON-NEOPLASTIC 3 OF 5 2 LYMPH NODE, ILIAC Examined 20 UNREMARKABLE 18 UNREMARKABLE 10 F 5 1 LYMPH NODE, MESENTERIC Examined: 18 UNREMARKABLE 20 Cellular debris NON-NEOPLASTIC 1 OF 5 1 HEMORRHAGE NON-NEOPLASTIC 1 OF 5 1 HEMORRHAGE NON-NEOPLASTIC 2 OF 5 2 Infiltration, mixed cell NON-NEOPLASTIC 1 OF 5 1 Infiltration, mixed cell NON-NEOPLASTIC 2 OF 5 2 Infiltration, mixed cell NON-NEOPLASTIC 2 OF 5 | Erythrocytosis NON-NEOPLASTIC 1 OF 5 1 Increased cellulanty NON-NEOPLASTIC 1 OF 5 2 Increased cellulanty NON-NEOPLASTIC 2 OF 5 7 Increased cellulanty NON-NEOPLASTIC 2 OF 5 7 Increased cellulanty NON-NEOPLASTIC 3 OF 5 2 LYMPH NODE_ILIAC Examined: 20 1 1 UNREMARKABLE NOT DONE 2 2 1 1 UNREMARKABLE NON-NEOPLASTIC 1 OF 5 1 | Erythrocytosis NON-NEOPLASTIC 1 OF 5 1 Increased cellularity NON-NEOPLASTIC 1 OF 5 2 1 Increased cellularity NON-NEOPLASTIC 2 OF 5 7 1 1 Increased cellularity NON-NEOPLASTIC 3 OF 5 2 1 1 1 UNREMARKABLE 10 18 1 </td <td>Erythrocytosis NON-NEOPLASTIC 1 OF 5 1 <th1< th=""> 1 <t< td=""><td>Erythrocytosis NON-NEOPLASTIC 1 OF 5 1 <th1< th=""> 1 <th1< th=""> 1 <th1< th=""> <th1< td=""><td>Erythrocytosis NON-NEOPLASTIC 1 OF 5 1 <th1< th=""> 1
 1 <th1< th=""> 1 <th1< th=""> <th1< td=""><td>Erythrocytosis NON-NEOPLASTIC 1 OF 5 1 <th1< th=""> 1 <th1< th=""> <th< td=""><td>Erythrocytosia NON-NEOPLASTIC 1 OF 5 2 0 0 Increased cellulanty NON-NEOPLASTIC 1 OF 5 2 0 0 Increased cellulanty NON-NEOPLASTIC 2 OF 5 2 0 0 Increased cellulanty NON-NEOPLASTIC 2 OF 5 2 0 0 UNREMARKABLE 10 1</td><td>Erythrocytosis NON-NEOPLASTIC 1 OF 5 1 0 0 Increased cellularity NON-NEOPLASTIC 1 OF 5 2 0 <</td><td>Erythrocytosis NON-NEOPLASTIC 1 OF 5 1 0 0 Increased cellularity NON-NEOPLASTIC 1 OF 5 2 0 0 1 Z 1 Z Increased cellularity NON-NEOPLASTIC 2 OF 5 7 0 1 Z 1 Z 0 Increased cellularity NON-NEOPLASTIC 2 OF 5 7 0 1 Z 1 Z 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1</td><td>Erythrocytosis NON-NEOPLASTIC 1 OF 5 1 0 1 <th1< th=""> 1 <th1< th=""> <th< td=""><td>Erythrocytosis NON-NEOPLASTIC 1 0 F 5 2 0 1 1 Increased cellulanty NON-NEOPLASTIC 1 0 F 5 2 0 1 1 1 Increased cellulanty NON-NEOPLASTIC 2 0 F 5 2 0 1 1 1 0 1 1 1 1 0 1 1 1 0 1 1 1 0 1 1 1 0 1 1 1 0 1 1 1 0 1 1 1 0 1 1 1 0 1 1 1 0 1 1 1 0 1 1 1 0 1 1 1 0 1 1 1 0 1 1 1 0 1 1 <td< td=""><td>Erythrocytosia NON-NEOPLASTIC 1 OF 5 1 0 1 1 Increased cellularity NON-NEOPLASTIC 1 OF 5 2 0 0 1</td><td>Erythrocytosis NON-NEOPLASTIC 1 OF 5 1 0 1 1 Increased cellularity NON-NEOPLASTIC 1 OF 5 2 0 1</td></td<></td></th<></th1<></th1<></td></th<></th1<></th1<></td></th1<></th1<></th1<></th1<></td></th1<></th1<></th1<></th1<></td></t<></th1<></td> | Erythrocytosis NON-NEOPLASTIC 1 OF 5 1 <th1< th=""> 1 <t< td=""><td>Erythrocytosis NON-NEOPLASTIC 1 OF 5 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 1 1 1 1 1 1 <th1< th=""> 1 <th1< th=""> 1 <th1< th=""> <th1< td=""><td>Erythrocytosis NON-NEOPLASTIC 1 OF 5 1 <th1< th=""> 1 <th1< th=""> 1 <th1< th=""> <th1< td=""><td>Erythrocytosis NON-NEOPLASTIC 1 OF 5 1 <th1< th=""> 1 <th1< th=""> <th< td=""><td>Erythrocytosia NON-NEOPLASTIC 1 OF 5 2 0 0 Increased cellulanty NON-NEOPLASTIC 1 OF 5 2 0 0 Increased cellulanty NON-NEOPLASTIC 2 OF 5 2 0 0 Increased cellulanty NON-NEOPLASTIC 2 OF 5 2 0 0 UNREMARKABLE 10 1</td><td>Erythrocytosis NON-NEOPLASTIC 1 OF 5 1 0 0 Increased cellularity NON-NEOPLASTIC 1 OF 5 2 0 <</td><td>Erythrocytosis NON-NEOPLASTIC 1 OF 5 1 0 0 Increased cellularity NON-NEOPLASTIC 1 OF 5 2 0 0 1 Z 1 Z Increased cellularity NON-NEOPLASTIC 2 OF 5 7 0 1 Z 1 Z 0 Increased cellularity NON-NEOPLASTIC 2 OF 5 7 0 1 Z 1 Z 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1</td><td>Erythrocytosis NON-NEOPLASTIC 1 OF 5 1 0 1 <th1< th=""> 1 <th1< th=""> <th< td=""><td>Erythrocytosis NON-NEOPLASTIC 1 0 F 5 2 0 1 1 Increased cellulanty NON-NEOPLASTIC 1 0 F 5 2 0 1 1 1 Increased cellulanty NON-NEOPLASTIC 2 0 F 5 2 0 1 1 1 0 1 1 1 1 0 1 1 1 0 1 1 1 0 1 1 1 0 1 1 1 0 1 1 1 0 1 1 1 0 1 1 1 0 1 1 1 0 1 1 1 0 1 1 1 0 1 1 1 0 1 1 1 0 1 1 1 0 1 1 <td< td=""><td>Erythrocytosia NON-NEOPLASTIC 1 OF 5 1 0 1 1 Increased cellularity NON-NEOPLASTIC 1 OF 5 2 0 0 1</td><td>Erythrocytosis NON-NEOPLASTIC 1 OF 5 1 0 1 1 Increased cellularity NON-NEOPLASTIC 1 OF 5 2 0 1
1 1 1 1</td></td<></td></th<></th1<></th1<></td></th<></th1<></th1<></td></th1<></th1<></th1<></th1<></td></th1<></th1<></th1<></th1<></td></t<></th1<> | Erythrocytosis NON-NEOPLASTIC 1 OF 5 1 <th1< th=""> 1 <th1< th=""> 1 <th1< th=""> <th1< td=""><td>Erythrocytosis NON-NEOPLASTIC 1 OF 5 1 <th1< th=""> 1 <th1< th=""> 1 <th1< th=""> <th1< td=""><td>Erythrocytosis NON-NEOPLASTIC 1 OF 5 1 <th1< th=""> 1 <th1< th=""> <th< td=""><td>Erythrocytosia NON-NEOPLASTIC 1 OF 5 2 0 0 Increased cellulanty NON-NEOPLASTIC 1 OF 5 2 0 0 Increased cellulanty NON-NEOPLASTIC 2 OF 5 2 0 0 Increased cellulanty NON-NEOPLASTIC 2 OF 5 2 0 0 UNREMARKABLE 10 1</td><td>Erythrocytosis NON-NEOPLASTIC 1 OF 5 1 0 0 Increased cellularity NON-NEOPLASTIC 1 OF 5 2 0 <</td><td>Erythrocytosis NON-NEOPLASTIC 1 OF 5 1 0 0 Increased cellularity NON-NEOPLASTIC 1 OF 5 2 0 0 1 Z 1 Z Increased cellularity NON-NEOPLASTIC 2 OF 5 7 0 1 Z 1 Z 0 Increased cellularity NON-NEOPLASTIC 2 OF 5 7 0 1 Z 1 Z 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1</td><td>Erythrocytosis NON-NEOPLASTIC 1 OF 5 1 0 1 <th1< th=""> 1 <th1< th=""> <th< td=""><td>Erythrocytosis NON-NEOPLASTIC 1 0 F 5 2 0 1 1 Increased cellulanty NON-NEOPLASTIC 1 0 F 5 2 0 1 1 1 Increased cellulanty NON-NEOPLASTIC 2 0 F 5 2 0 1 1 1 0 1 1 1 1 0 1 1 1 0 1 1 1 0 1 1 1 0 1 1 1 0 1 1 1 0 1 1 1 0 1 1 1 0 1 1 1 0 1 1 1 0 1 1 1 0 1 1 1 0 1 1 1 0 1 1 1 0 1 1 <td< td=""><td>Erythrocytosia NON-NEOPLASTIC 1 OF 5 1 0 1 1 Increased cellularity NON-NEOPLASTIC 1 OF 5 2 0 0 1</td><td>Erythrocytosis NON-NEOPLASTIC 1 OF 5 1 0 1 1 Increased cellularity NON-NEOPLASTIC 1 OF 5 2 0 1
 1 1</td></td<></td></th<></th1<></th1<></td></th<></th1<></th1<></td></th1<></th1<></th1<></th1<></td></th1<></th1<></th1<></th1<> | Erythrocytosis NON-NEOPLASTIC 1 OF 5 1 <th1< th=""> 1 <th1< th=""> 1 <th1< th=""> <th1< td=""><td>Erythrocytosis NON-NEOPLASTIC 1 OF 5 1 <th1< th=""> 1 <th1< th=""> <th< td=""><td>Erythrocytosia NON-NEOPLASTIC 1 OF 5 2 0 0 Increased cellulanty NON-NEOPLASTIC 1 OF 5 2 0 0 Increased cellulanty NON-NEOPLASTIC 2 OF 5 2 0 0 Increased cellulanty NON-NEOPLASTIC 2 OF 5 2 0 0 UNREMARKABLE 10 1</td><td>Erythrocytosis NON-NEOPLASTIC 1 OF 5 1 0 0 Increased cellularity NON-NEOPLASTIC 1 OF 5 2 0 <</td><td>Erythrocytosis NON-NEOPLASTIC 1 OF 5 1 0 0 Increased cellularity NON-NEOPLASTIC 1 OF 5 2 0 0 1 Z 1 Z Increased cellularity NON-NEOPLASTIC 2 OF 5 7 0 1 Z 1 Z 0 Increased cellularity NON-NEOPLASTIC 2 OF 5 7 0 1 Z 1 Z 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1</td><td>Erythrocytosis NON-NEOPLASTIC 1 OF 5 1 0 1 <th1< th=""> 1 <th1< th=""> <th< td=""><td>Erythrocytosis NON-NEOPLASTIC 1 0 F 5 2 0 1 1 Increased cellulanty NON-NEOPLASTIC 1 0 F 5 2 0 1 1 1 Increased cellulanty NON-NEOPLASTIC 2 0 F 5 2 0 1 1 1 0 1 1 1 1 0 1 1 1 0 1 1 1 0 1 1 1 0 1 1 1 0 1 1 1 0 1 1 1 0 1 1 1 0 1 1 1 0 1 1 1 0 1 1 1 0 1 1 1 0 1 1 1 0 1 1 1 0 1 1 <td< td=""><td>Erythrocytosia NON-NEOPLASTIC 1 OF 5 1 0 1 1 Increased cellularity NON-NEOPLASTIC 1 OF 5 2 0 0 1</td><td>Erythrocytosis NON-NEOPLASTIC 1 OF 5 1 0 1 1 Increased cellularity NON-NEOPLASTIC 1 OF 5 2 0 1</td></td<></td></th<></th1<></th1<></td></th<></th1<></th1<></td></th1<></th1<></th1<></th1<> | Erythrocytosis NON-NEOPLASTIC 1 OF 5 1
 1 <th1< th=""> 1 <th1< th=""> <th< td=""><td>Erythrocytosia NON-NEOPLASTIC 1 OF 5 2 0 0 Increased cellulanty NON-NEOPLASTIC 1 OF 5 2 0 0 Increased cellulanty NON-NEOPLASTIC 2 OF 5 2 0 0 Increased cellulanty NON-NEOPLASTIC 2 OF 5 2 0 0 UNREMARKABLE 10 1</td><td>Erythrocytosis NON-NEOPLASTIC 1 OF 5 1 0 0 Increased cellularity NON-NEOPLASTIC 1 OF 5 2 0 <</td><td>Erythrocytosis NON-NEOPLASTIC 1 OF 5 1 0 0 Increased cellularity NON-NEOPLASTIC 1 OF 5 2 0 0 1 Z 1 Z Increased cellularity NON-NEOPLASTIC 2 OF 5 7 0 1 Z 1 Z 0 Increased cellularity NON-NEOPLASTIC 2 OF 5 7 0 1 Z 1 Z 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1</td><td>Erythrocytosis NON-NEOPLASTIC 1 OF 5 1 0 1 <th1< th=""> 1 <th1< th=""> <th< td=""><td>Erythrocytosis NON-NEOPLASTIC 1 0 F 5 2 0 1 1 Increased cellulanty NON-NEOPLASTIC 1 0 F 5 2 0 1 1 1 Increased cellulanty NON-NEOPLASTIC 2 0 F 5 2 0 1 1 1 0 1 1 1 1 0 1 1 1 0 1 1 1 0 1 1 1 0 1 1 1 0 1 1 1 0 1 1 1 0 1 1 1 0 1 1 1 0 1 1 1 0 1 1 1 0 1 1 1 0 1 1 1 0 1 1 1 0 1 1 <td< td=""><td>Erythrocytosia NON-NEOPLASTIC 1 OF 5 1 0 1 1 Increased cellularity NON-NEOPLASTIC 1 OF 5 2 0 0 1</td><td>Erythrocytosis NON-NEOPLASTIC 1 OF 5 1 0 1 1 Increased cellularity NON-NEOPLASTIC 1 OF 5 2 0 1</td></td<></td></th<></th1<></th1<></td></th<></th1<></th1<> | Erythrocytosia NON-NEOPLASTIC 1 OF 5 2 0 0 Increased cellulanty NON-NEOPLASTIC 1 OF 5 2 0 0 Increased cellulanty NON-NEOPLASTIC 2 OF 5 2 0 0 Increased cellulanty NON-NEOPLASTIC 2 OF 5 2 0 0 UNREMARKABLE 10 1 | Erythrocytosis NON-NEOPLASTIC 1 OF 5 1 0 0 Increased cellularity NON-NEOPLASTIC 1 OF 5 2 0 < | Erythrocytosis
NON-NEOPLASTIC 1 OF 5 1 0 0 Increased cellularity NON-NEOPLASTIC 1 OF 5 2 0 0 1 Z 1 Z Increased cellularity NON-NEOPLASTIC 2 OF 5 7 0 1 Z 1 Z 0 Increased cellularity NON-NEOPLASTIC 2 OF 5 7 0 1 Z 1 Z 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 | Erythrocytosis NON-NEOPLASTIC 1 OF 5 1 0 1 <th1< th=""> 1 <th1< th=""> <th< td=""><td>Erythrocytosis NON-NEOPLASTIC 1 0 F 5 2 0 1 1 Increased cellulanty NON-NEOPLASTIC 1 0 F 5 2 0 1 1 1 Increased cellulanty NON-NEOPLASTIC 2 0 F 5 2 0 1 1 1 0 1 1 1 1 0 1 1 1 0 1 1 1 0 1 1 1 0 1 1 1 0 1 1 1 0 1 1 1 0 1 1 1 0 1 1 1 0 1 1 1 0 1 1 1 0 1 1 1 0 1 1 1 0 1 1 1 0 1 1 <td< td=""><td>Erythrocytosia NON-NEOPLASTIC 1 OF 5 1 0 1 1 Increased cellularity NON-NEOPLASTIC 1 OF 5 2 0 0 1</td><td>Erythrocytosis NON-NEOPLASTIC 1 OF 5 1 0 1 1 Increased cellularity NON-NEOPLASTIC 1 OF 5 2 0 1</td></td<></td></th<></th1<></th1<> | Erythrocytosis NON-NEOPLASTIC 1 0 F 5 2 0 1 1 Increased cellulanty NON-NEOPLASTIC 1 0 F 5 2 0 1 1 1 Increased cellulanty NON-NEOPLASTIC 2 0 F 5 2 0 1 1 1 0 1 1 1 1 0 1 1 1 0 1 1 1 0 1 1 1 0 1 1 1 0 1 1 1 0 1 1 1 0 1 1 1 0 1 1 1 0 1 1 1 0 1 1 1 0 1 1 1 0 1 1 1 0 1 1 1 0 1 1 <td< td=""><td>Erythrocytosia NON-NEOPLASTIC 1 OF 5 1 0 1 1 Increased cellularity NON-NEOPLASTIC 1 OF 5 2 0 0 1</td><td>Erythrocytosis NON-NEOPLASTIC 1 OF 5 1 0 1 1 Increased cellularity NON-NEOPLASTIC 1 OF 5 2 0 1</td></td<> | Erythrocytosia NON-NEOPLASTIC 1 OF 5 1 0 1 1 Increased cellularity NON-NEOPLASTIC 1 OF 5 2 0 0 1 | Erythrocytosis NON-NEOPLASTIC 1 OF 5 1 0 1 1 Increased cellularity NON-NEOPLASTIC 1 OF 5 2 0 1 |

Histopathological findings in numbers are listed in one table using few clicks

Microscopic Findings-Graph



Different histopathological findings in different organs in one graph





THANK YOU




Proof of Concept Pilot Studies


Susan DeHaven

Translational Medicine & Early Development Sanofi US Inc.


Roadmap to SEND for CBER



• SEND for CBER Team was a strong collaboration between FDA and CDISC SEND Experts



Proof of Concept Pilot Studies



Proof of Concept Pilot Endpoints

DA

Endpoints evaluated:

- Clinical observations
- Local tolerance
- Ophthalmoscopy
- Mortality
- Body weight, Food consumption
- Plasma activity and antigen levels
- Immunogenicity/Antibody development
- Clinical pathology standard hematology , clinical chemistry, urinalysis
- Terminal procedures: comprehensive macroscopic and microscopic evaluation
- Organ weight
- Body temperature
- Specifically noted for Vaccines: C-reactive protein (in rabbits)





Pilot Studies: domains & endpoints

Endpoint	Domain Study 1	Domain Study 2	Domain Study 3	Domain Study 4
Clinical observations	cl	cl	cl	cl
Local reactions				cl
Ophthalmoscopy		cl		cl
Mortality		ds	ds	ds
Body weight, body weight gain	bw, bg	bw	bw	bw, bg
Food consumption		fw		fw
Antigen levels	is*			is*
Immunogenicity/Antibodies			is*	
Protein expression, transgene expression, vector conc.			рс	
Hematology	lb	lb	lb	lb
Clinical chemistry	lb	lb	lb	lb
Coagulation	lb	lb	lb	lb
Urinalysis	lb			
Macroscopic evaluation		ma	ma	ma
Microscopic evaluation		mi	mi	mi
Organ weights		om		om
Body temperature		VS		VS
C-reactive protein (rabbits)		lb		lb

FDA

Each pilot study included:

- study design
- nsdrg
- define file
- study report

*is – immunogenicity specimens domain, was piloted as a custom domain, based on SDTM model because it is not yet a SEND standard (current CDISC work in progress)

Pilot Outcomes: *Study Findings Considerations*



KEY BENEFITS

Quick data overview

Consistent terms and units

Original results available

Alignment with Study Report • Using SEND data enables quick overview of data, such as:

Seeing differences between scheduled body weight measurements, Identifying body temperatures above normal, Determining key timepoints of collection relative to dosing (i.e. was CRP measured 24, 48 hrs postdose?)

- Correct mapping to controlled terminology and consistent units within/between SEND data, Study Report and nSDRG is helpful
- Use of variables in the SEND data needs to be consistent with SEND IG definitions, for clarity and utility
- Original result values in SEND (--ORRES) are very useful to see the full text of the observation as collected. Standardization of --ORRES parses content into parent domain variables, with possibly comments and/or supplemental qualifiers, such that sometimes difficult to reconstruct.
- Quantification of LOQ or BLQ values are useful when included in supplemental qualifiers





- Study designs for single and repeat dose tox studies fit into SEND trial design domains
 - Study design descriptions in nSDRG are very helpful
- Important information dependencies:
 - Clear description of differences between SEND dataset and study report in nSDRG
 - Consistency between Define file and dataset content
 - Explanation of extended terminology in nSDRG

Pilot Outcomes: *Other Considerations*



- Study "hybrid" e-data submissions are possible
 - Nonclinical studies submitted to CBER can include some endpoints modeled in SEND and other endpoints not modeled in SEND
 - Efficacy endpoints within a tox study are not modeled in SEND IG 3.1
 - Not all endpoints for CBER studies are yet in scope of SEND
- All data that can be submitted in SEND is helpful to the review
 - Biodistribution data can be modeled using PC domain, though not specifically mentioned in SEND IG yet
 - "IS" Custom domain is not required, but can be accepted, or data (such as ADA) may fit in LB domain, under SEND IG 3.1
 - Clarify for Reviewers which data has been submitted in e-format or not, in nSDRG
- As future SEND IG versions come into publication and adoption by CBER, e-data scope is expected to expand accordingly

SEND For CBER Team Future Ongoing Mission



- Support CDISC SEND Team to include CBER considerations in standards development by:
 - Participating in domain working groups for Exposure, Immunogenicity Specimens and modeling of dermal/ocular findings
 - Contributing to relevant controlled terminology development
 - Contributing to CDISC SEND IG version 3.2 scope decisions and development
 - Remain engaged, as future SEND IG versions come into publication and adoption by CBER, scope is expected to expand accordingly (i.e. repro studies)

• Support FDA's data standards efforts by:

- Developing recommendations for Technical Conformance Guide
- Considering conformance and business rules applied to CBER e-data submissions
- Communicating Proof of Concept Pilot and other team deliverables to industry stakeholders





- FDA Data Standards Catalog
- Federal Register Notice regarding SEND for CBER
- FDA Data Standards Program Action Plan
- SEND for CBER wiki site

Summary



- CBER is ready to support SEND data for nonclinical study submissions
- Requirement date of CBER SEND submission is March 15, 2023
- Future development on SENDIG for CBER



Questions?

cber-edata@fda.hhs.gov